Efficacy of Flu Antivirals in Reducing Illness Duration and Complications

Treatment Efficacy: Symptom Reduction

The Centers for Disease Control and Prevention recommends that flu antivirals reduce illness duration by 0.7-1.5 days in otherwise healthy adults when initiated within 48 hours of symptom onset 1, 2
The American Academy of Pediatrics notes that oseltamivir shortens symptoms by 17.6 hours in children 3
The World Health Organization states that early treatment with antivirals reduces illness severity by up to 38% compared to placebo 2
The greatest benefit of antiviral treatment occurs when started within 30-36 hours of symptom onset, with diminishing returns after 48 hours 1

The Centers for Disease Control and Prevention reports a 50% reduction in pneumonia risk in patients with laboratory-confirmed influenza when treated with antivirals 1, 3, 2
The American Academy of Pediatrics notes a 34% reduction in otitis media in children treated with antivirals 3, 2
The World Health Organization states that antivirals provide a significant mortality benefit in hospitalized patients, even when treatment starts beyond 48 hours 3, 2
Antiviral treatment reduces hospital length of stay by 2 days when treated within 48 hours versus after 48 hours 4

The Centers for Disease Control and Prevention recommends that antivirals demonstrate 70-90% protective efficacy for seasonal prophylaxis in unvaccinated healthy adults 4, 2
The American Academy of Pediatrics notes that antivirals show 68-89% efficacy for post-exposure household prophylaxis when started within 48 hours of exposure 4, 3, 2
The World Health Organization states that antivirals reduce influenza illness by 92% in nursing home residents during a 6-week prophylaxis study 4

The Centers for Disease Control and Prevention recommends that high-risk and severely ill patients, including hospitalized patients, immunocompromised individuals, elderly patients, pregnant women, and children under 2 years of age, derive the greatest benefit from antiviral treatment 1, 3
The American Academy of Pediatrics notes that patients with chronic cardiac, pulmonary, or other chronic diseases also benefit from antiviral treatment 4, 3

The World Health Organization states that common side effects of oseltamivir are generally mild and transient, including nausea and vomiting, which can be reduced by taking the medication with food 3, 2
The Centers for Disease Control and Prevention notes that zanamivir is associated with upper respiratory symptoms and a risk of bronchospasm in patients with underlying airways disease 2

The American Academy of Pediatrics recommends treatment dosing of 75 mg twice daily for 5 days for adults and adolescents ≥13 years, and weight-based dosing for children 3, 2
The Centers for Disease Control and Prevention notes that prophylaxis dosing is the same as treatment dosing but once daily instead of twice daily 3, 2

The Centers for Disease Control and Prevention recommends oseltamivir for treatment and prophylaxis of acute, uncomplicated illness due to both influenza A and B infection, with a reduction in duration of uncomplicated influenza B illness by approximately 1 day compared to placebo when initiated within 48 hours of symptom onset 5, 6, 7
Oseltamivir reduces pneumonia risk by approximately 50% in patients with laboratory-confirmed influenza (both A and B) 5
The American Academy of Pediatrics notes that oseltamivir decreases secondary complications including otitis media by 34% in children 5

The World Health Organization states that oseltamivir demonstrates 82% efficacy in preventing febrile, laboratory-confirmed influenza illness (both A and B) when used for seasonal prophylaxis 8, 6, 7
Post-exposure household prophylaxis shows 68-89% efficacy when initiated within 48 hours of contact with an infected individual 6

The Centers for Disease Control and Prevention reports that only 1.6% of influenza B viruses showed resistance to oseltamivir in one study, and no human-to-human transmission of resistant viruses has been documented 9